Breast angiosarcoma

Summary

Breast angiosarcoma (MONDO:0003024) is a disease. Molecularly, KDR Overexpression confers sensitivity to Sunitinib in Breast Angiosarcoma (CIViC Level C). A subtype of breast sarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Precision-medicine evidence (CIViC): 1 subtype–drug association

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	breast angiosarcoma
Mondo ID	MONDO:0003024
MeSH	C536368
DOID	DOID:4511
ICD-11	2050477809
NCIT	C5184
UMLS	C1332614
MedGen	272382
GARD	0009974
Anatomy (UBERON)	UBERON:0000310
Is cancer (heuristic)	no

Also known as: angiosarcoma (disease) of breast · angiosarcoma of breast · angiosarcoma of the breast · BA · breast angiosarcoma · breast angiosarcoma (disease) · breast hemangiosarcoma · hemangiosarcoma of breast · hemangiosarcoma of the breast

Disease family

This is a subtype of breast sarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › thoracic cancer › breast cancer › breast sarcoma › breast angiosarcoma

Related subtypes (6): breast rhabdomyosarcoma, breast leiomyosarcoma, breast liposarcoma, breast fibrosarcoma, breast extraskeletal osteosarcoma, breast synovial sarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 1 predictive associations from 1 curated evidence items.

Molecular subtype	Therapy	Effect	Level	CIViC
KDR Overexpression	Sunitinib	Sensitivity/Response	CIViC C	EID5910